Key Highlights
- CG Oncology (NASDAQ:CGON) gained 13.95% on November 16, 2026, after its Phase 3 PIVOT-006 trial showed a 68% lower risk of bladder cancer recurrence, a hazard ratio of 0.32.
- Lexeo Therapeutics climbed 12.54% as high-dose LX2020 lowered dangerous heart rhythm episodes by 80% on average, and the FDA indicated it is open to that measure as a pivotal endpoint.
- Despite a Phase 3 depression win, Helus Pharma lost 13.53%, and Alpha Tau Medical lost 10.54% even with a 100% response rate among six evaluable glioblastoma patients.
- Aclaris Therapeutics dropped 8.04% after its Phase 2 eczema trial of bosakitug missed the primary endpoint and every secondary one, on a day when the Nasdaq Composite fell 2.49%.
1. CG Oncology (NASDAQ:CGON)
The cleanest result of the day came from CG Oncology (NASDAQ:CGON). In its Phase 3 PIVOT-006 trial, 367 patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer were randomized after surgery to cretostimogene or to surveillance. Delivered straight into the bladder, the gene therapy cut recurrence risk by 68%, with a hazard ratio of 0.32, a 95% confidence interval of 0.23 to 0.45 and a p-value under 0.0001. Median follow-up was 17 months. For patients who may be treated over long periods, safety counted just as much, and no grade 3 or higher treatment-related adverse events or treatment-related discontinuations occurred. Before the open the stock briefly traded more than 30% higher, and it closed up 13.95% while the broader market fell. A commercial path is already mapped out. Approval in BCG-unresponsive disease, supported by the BOND-003 trial, is being pursued, and the company plans to widen that first application to high-grade papillary-only disease by the end of March 2027. A second application backed by PIVOT-006 would follow in the second quarter of 2027, and Manufacturing for both filings is complete. A major urology meeting on December 2, 2026, will host the full results. Competition, pricing and the cost of building a commercial operation remain open questions.
2. Lexeo Therapeutics (NASDAQ:LXEO)
Encouraging data and a regulatory signal came together at Lexeo Therapeutics (NASDAQ:LXEO). Ten patients have been dosed in its HEROIC-PKP2 study of LX2020, a one-time gene therapy for PKP2 arrhythmogenic cardiomyopathy: three at a low dose and seven at a dose three times higher. Among high-dose patients, non-sustained ventricular tachycardia episodes dropped 80% on average from baseline, with six of seven improving, while premature ventricular contractions declined 44%, with five of seven improving. PKP2 protein rose with dose in biopsies. Tolerability was generally good, although raised liver enzymes in high-dose patients were managed with standard treatment, and one patient had a serious episode of ventricular tachycardia three months after dosing. Perhaps the bigger news is the FDA's openness to non-sustained ventricular tachycardia as the primary surrogate endpoint in a pivotal study under the Accelerated Approval pathway, which would permit a shorter, smaller trial. The design is to be finalised in the first half of 2027, with the study starting in the second half. Early on the stock jumped as much as 28%, then closed up 12.54%. Cash of USD 219.1 million should last into 2028, enough to cover the start of the pivotal trial but probably not its completion.
3. Helus Pharma (NASDAQ:HELP)
A positive trial can still be followed by a sell-off, as Helus Pharma (NASDAQ:HELP) demonstrates. Its Phase 3 APPROACH study enrolled 222 adults with major depressive disorder whose symptoms had not responded well enough to existing treatment. By six weeks, MADRS depression scale scores had dropped 19.5 points on HLP003, a deuterated form of psilocin, compared with 11.9 on placebo, a 7.6 point gap, with a 5.0 point gap from day two and a 7.0 point gap at 12 weeks. A response was seen in 56.3% of patients at six weeks against 28.2% on placebo, and 50.9% reached remission against 18.2%. Three serious adverse events related to treatment were reported, along with no new safety signals. Trading was extreme. Before the open shares ranged between USD 4.85 and USD 11.22 against a prior close of USD 8.87, climbed about 15% early, dropped about 30% at one point and ended down 13.53%. No single explanation was offered. Selling on widely anticipated news, questions over how regulators will view the serious adverse events in a drug class requiring supervised dosing, and a weak day for Growth Stocks are likely factors. Since one positive Phase 3 trial usually falls short of what depression approval needs, the key test is the second pivotal study, EMBRACE, due to report in the fourth quarter of 2027.
4. Alpha Tau Medical (NASDAQ:DRTS)
In its first session after an update from the US REGAIN trial of Alpha DaRT in recurrent glioblastoma, Alpha Tau Medical (NASDAQ:DRTS) fell 10.54%. Headline numbers were strong: as of November 11 all eight treated patients were alive, and all six evaluable patients responded, five with complete responses and one with a partial response showing a 58% reduction in tumor measurements. Median follow-up was 6.9 months. Investors zeroed in on the details. Four of the six evaluable patients showed necrosis or suspected necrosis, described as asymptomatic, and in two of them scans cannot yet distinguish treatment effect from tumor growth, so more imaging and possibly a biopsy are under way. Reclassifying either case as progression would lower the response rate. Another patient had progression outside the treated area about nine months after treatment. No unanticipated serious adverse events occurred. During the morning investor call the stock was down 7.70%, and it closed 10.54% lower as speculative healthcare names were sold. Enrolment will continue toward up to 20 patients, which the company says may support a future Marketing submission. Limitations are clear, namely a very small sample, short follow-up and no control arm, so the two unclear cases are the next data points to watch.
5. Aclaris Therapeutics (NASDAQ:ACRS)
Only one of the five was an outright failure, and it belonged to Aclaris Therapeutics (NASDAQ:ACRS). Bosakitug, an antibody blocking the TSLP signalling protein, did not meet the primary endpoint in its Phase 2 ADMIRATION trial in moderate-to-severe atopic dermatitis, which was the relative change in eczema severity scores at week 24, nor any secondary endpoint. Robust target engagement, reduced markers of several inflammatory pathways and good general tolerability were seen, but none translated into clinical benefit over placebo. Detailed efficacy numbers and patient counts were not included in the release. A decline of 8.04% was modest for a clean miss, hinting that investors had set limited expectations for the program. On the same morning Aclaris began a Phase 2b trial of modzatinib, an oral drug blocking the ITK and JAK3 enzymes, in lichen planus, and said it expects to file an investigational new drug application for ATI-9494 this quarter. For ATI-052, a bispecific antibody targeting both TSLP and the IL-4 receptor, a Phase 2b trial in eosinophilic esophagitis is planned for the first quarter of 2027. TSLP blockade alone in eczema now faces questions after the failure. The data came without an update to cash runway, so funding is the main risk.
Where Things Stand
CG Oncology's readout holds up best among the top 5 clinical readouts of November 16, thanks to a large randomized Phase 3 effect, clean safety and two filings planned by mid-2027. Lexeo's small study gained weight from the FDA's openness to its endpoint, Helus has strong data but needs a second pivotal trial, Alpha Tau's response rate hinges on two unclear scans, and Aclaris has to rebuild around its other programs. The next fixed date is CG Oncology's presentation on December 2.
_11_17_2026_18_59_44_560836.jpg)





Please wait processing your request...